Mangoceuticals, INC 8-K filings

Mangoceuticals, Inc. enters into a consulting agreement with 6330 Investment & Consulting Gmbh for strategic business advisory services, issuing restricted common stock and warrants in consideration.

Mangoceuticals amends its patent purchase agreement with Intramont Technologies, allowing development expenses to offset remaining cash payments, and secures $350,000 through a common stock subscription agreement.

Mangoceuticals is researching a non-invasive, water-based solution to combat avian flu in the poultry industry.

Mangoceuticals, Inc. announces a private placement of $105,000 through the sale of restricted common stock and an amendment to the Chief Operating Officer's employment agreement, increasing her responsibilities and compensation.

Mangoceuticals, Inc. has entered into several agreements including assignment of contracts to a subsidiary, a service agreement, and a distribution agreement to expand its business operations.

Mangoceuticals, Inc. has converted $150,000 of debt into equity, appointed Antonios Isaac as President and Director, and completed a final closing of a Series B Preferred Stock sale.

Mangoceuticals, Inc. establishes Series A Super Majority Voting Preferred Stock, granting significant voting rights to the holder.

Mangoceuticals, Inc. closed a private placement offering, selling Series B Preferred Stock and warrants to institutional investors, raising $990,000.

Mangoceuticals, Inc. has entered into securities purchase agreements to raise $1.25 million through the sale of preferred stock and warrants.

Mangoceuticals, Inc. has acquired a patent for mushroom-derived nutraceutical compositions and restructured its operations by transferring assets to a newly formed subsidiary, Mango & Peaches Corp.

Mangoceuticals, Inc. entered into a service agreement with Greentree Financial Group, Inc. for compliance services, issuing 40,000 shares and agreeing to pay $40,000, and also sold 75,000 shares for $159,950 through an existing equity purchase agreement.

Mangoceuticals, Inc. has entered into a consulting agreement with Eugene M. Johnston, appointing him as Chief Financial Officer, effective October 1, 2024.

Mangoceuticals, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after a reverse stock split.

Mangoceuticals, Inc. sold 33,333 shares of common stock for $78,787 and converted 200 shares of Series B Preferred Stock into 93,299 shares of common stock valued at $220,000.

Mangoceuticals, Inc. has entered into a $150,000 promissory note with Cohen Enterprises and initiated a strategic review process to maximize shareholder value.

Mangoceuticals, Inc. has issued a press release refuting claims by Eli Lilly that it improperly copied their weight-loss medications, Zepbound and Mounjaro, and stating their intent to vigorously defend themselves against the lawsuit.

Mangoceuticals, Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective October 16, 2024.

Mangoceuticals has announced the launch of its oral Tirzepatide weight loss treatment, branded as Trim, offering a convenient alternative to injectable therapies.

Mangoceuticals, Inc. issued shares and warrants to consultants and a marketing firm, and sold shares to Platinum Point Capital under an existing agreement.

Mangoceuticals, Inc. has launched its oral Semaglutide weight loss treatment, branded as 'Slim', aiming to capitalize on the growing GLP-1 market.

Mangoceuticals, Inc. has sold an additional 250 shares of Series B Preferred Stock for $250,000 as part of its ongoing financing agreement.

Mangoceuticals sold an additional 500 shares of Series B Preferred Stock for $500,000 and increased the CEO's monthly car allowance from $1,500 to $2,500.

Mangoceuticals, Inc. announced a significant increase in shareholder equity and revenue for the first half of 2024, driven by strategic acquisitions and product expansion.

Mangoceuticals has entered into a strategic partnership with ISFLST to distribute its men's health products in Asia Pacific and Latin America (excluding Mexico).

Mangoceuticals, Inc. has amended its securities purchase agreement with Platinum Point Capital LLC, adjusting the closing schedule and issuing new warrants.

Mangoceuticals, Inc. held its 2024 Annual Meeting of Stockholders, where all six proposals, including the election of directors and approval for the issuance of additional shares, were approved.

Mangoceuticals, Inc. issued shares of common stock to a consultant and several executives and directors as compensation for services and bonuses.

Mangoceuticals has been granted a 180-day extension to meet Nasdaq's minimum bid price requirement and has received conditional approval for compliance with the minimum stockholders' equity requirement.

Mangoceuticals, Inc. has acquired a global patent portfolio for an oral solution aimed at preventing infections, marking its entry into the non-prescription nutraceutical market.

Mangoceuticals, Inc. has entered into agreements to sell preferred stock and warrants for $1.65 million and secured a $25 million equity line of credit.